AspireAssist system is an endoscopic alternative to weight loss surgery for people with moderate to severe obesity.
It is indicated for adults with a BMI of 35 to 55 who have not succeeded with more conservative therapies.
AspireAssist system, which offers a novel approach to obesity treatment through portion control, can be used in conjunction with diet and exercise counselling and medical monitoring.
The system can be implanted in a 15-minute outpatient procedure. It is fully reversible, and does not alter the patient’s internal anatomy.
The company assessed AspireAssist in the Pathway study, a 171-subject multicenter trial in the US.
Patients lost an average of 46 pounds in the first year in a previous randomized US clinical study with the AspireAssist system.
Aspire Bariatrics president and CEO Katherine Crothall said: "We are very happy to be able now to offer this life-changing therapy in the US to patients with obesity; many of whom felt, until now, that there were few viable solutions for them."
